AndhraNews.net
Home » Business News » 2011 » December » December 7, 2011

Basilea appoints Chief Financial Officer


December 7, 2011 - Basel, Switzerland

Basilea Pharmaceutica AG /Basilea appoints Chief Financial Officer. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Basilea Pharmaceutica Ltd. (SIX: BSLN)today announced that Joachim Blatter has been appointed Chief FinancialOfficer(CFO) of Basilea Pharmaceutica International Ltd.

Joachim Blatter will join Basilea mid-January 2012 as Chief FinancialOfficerand member of the management committee. In addition to finance he will beresponsible for information technology and internal services reporting toChiefOperating Officer Ronald Scott, who has been acting as ad interim CFO.

Joachim Blatter, a German citizen, has held various senior financepositions,most recently as CFO of Swissmetal Industries Ltd. in Dornach, Switzerland.Mr.Blatter was previously CFO of Alcan Singen GmbH and Managing Director ofAlcanHoldings Germany GmbH. He holds a degree in business administration fromtheUniversity of Cologne, Germany, and is a certified management accountant aswellas a certified financial manager.

Dr. Anthony Man, Chief Executive Officer, commented: "We are very pleasedtowelcome Joachim Blatter to Basilea's executive management team as ChiefFinancial Officer. He has over 20 years of international experience infinancialand operational management. In his new position, he will be able to buildonBasilea's strong financial foundation with a continued focus on prudentfinancial management."

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, andlisted onthe SIX Swiss Exchange (SIX: BSLN). Basilea Pharmaceutica InternationalLtd.'sfully integrated research and development operations are focused onAntibiotics,antifungals and oncology drugs, as well as on the development ofdermatologydrugs, targeting the medical challenge of resistance and non-response tocurrenttreatment options in the hospital and specialty care setting.

Basilea is currently marketing Toctino® (alitretinoin), the onlyapprovedtreatment for adults with severe chronic hand eczema unresponsive to potenttopical corticosteroids, in Denmark, Finland, France, Germany, Norway,Switzerland and the United Kingdom and has appointed distributors forToctino®in other selected European markets, Canada, Israel, Mexico and the RepublicofKorea. A phase III clinical program on alitretinoin for the treatment ofseverechronic hand eczema is ongoing in the U.S.

For its phase III compound isavuconazole, a potential best-in-class azoleantifungal for the treatment of life-threatening invasive fungalinfections, thecompany has entered into a license, co-development and co-promotionagreementwith Astellas Pharma Inc.

In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporinantibiotic, for the first-line treatment of potentially life-threateningresistant bacterial infections. Ceftobiprole has a broad coverage of bothGram-positive bacteria, including MRSA, and many clinically important Gram-negativebacteria such as Pseudomonas spp.

Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram-negative infections, and the oncology drug BAL101553 for the treatment ofdrug-resistant cancers are in phase I clinical testing.

Disclaimer

This communication expressly or implicitly contains certain forward-lookingstatements concerning Basilea Pharmaceutica Ltd. and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors, which could cause the actual results, financial condition,performanceor achievements of Basilea Pharmaceutica Ltd. to be materially differentfromany future results, performance or achievements expressed or implied bysuchforward-looking statements. Basilea Pharmaceutica Ltd. is providing thiscommunication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, futureevents or otherwise.

This press release can be downloaded from www.basilea.com.

Press release (PDF):http://hugin.info/134390/R/1569611/487930.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright andother applicable laws; and

(ii) they are solely responsible for the content, accuracy andoriginality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1569611]

For further information, please contact:


Media Relations
Peer Nils Schröder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact


Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact

MarketWire

Comment on this story

Share